The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an ...
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Sanofi to receive an exclusive right of first negotiation for Ventyx’s CNS-penetrant NLRP3 inhibitor VTX3232SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VTYX) (“Ventyx”), a clinical-stage ...
Sanofi invests $27 million in Ventyx Biosciences at $3.8243 per share. The investment will fund VTX3232 trials for ...
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as ...
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target ...
SAN DIEGO, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that ...
What Factors Have Led to Ventyx Biosciences Inc (VTYX) Stock Trading -93.48% Below Its 52-Week High?
On Thursday, Ventyx Biosciences Inc (VTYX) stock saw a decline, ending the day at $2.36 which represents a decrease of $-0.03 or -1.26% from the prior close of $2.39. The stock opened at $2.43 and ...
Ventyx Biosciences Inc (VTYX) stock saw a modest uptick, ending the day at $2.46 which represents a slight increase of $0.16 or 6.96% from the prior close of $2.3. The stock opened at $2.66 and ...
Oppenheimer analyst Jeff Jones maintained a Buy rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback